Trial Profile
A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients With Advanced Uveal Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 03 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 29 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.